NEW YORK (GenomeWeb News) – 23andMe today announced the expansion of its online study conducted with Genentech for the biotech firm's oncology drug Avastin (bevacizumab).

In a post on 23andMe's blog, the Mountain View, Calif.-based company said that its study with Genentech, called InVite, is now open to any patient in the US who used Avastin before 2013 for treatment of metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, relapsed glioblastoma, metastatic renal cell carcinoma, or metastatic breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene regulation changes linked to human brain evolution, and more.

The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.

Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.

A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.